This article was originally published in Scrip
Pharma's approach to transparency is not always wholehearted. Its position on proposed revisions to the European Union's Transparency Directive, for instance, is in essence that drug pricing is a matter for bilateral discussions between industry and the reimbursement authorities in each country, and that the detailed outcomes of those discussions should not be shared across member states. That's a nice point of principle – the business even of public companies is private – but whether it is sustainable in a marketplace where cost and value are becoming more strongly linked is debatable.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.